Coherus Oncology, Inc. Financing Cash Flow
Coherus Oncology, Inc. (CHRS) reported Financing Cash Flow of $53.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- Coherus Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $144.00K.
- Coherus Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $53.59M.
- Coherus Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $8.08M, a 3398.27% increase year-over-year.
- Coherus Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $2.00K.
- Coherus Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2025 was -$273.70M.
- Coherus Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$186.97M.
- Coherus Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $54.33M, a 4.72% increase from fiscal 2021.
- Coherus Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2021 was $51.88M, a 76.83% decline from fiscal 2020.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $144.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $53.73M 10-Q · filed 2026-08-05 | $61.81M derived: sum of 3 quarters · filed 2026-08-05 | $61.82M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $53.59M 10-Q · filed 2026-05-11 | $61.67M derived: sum of 2 quarters · filed 2026-05-11 | $61.67M derived: sum of 3 quarters · filed 2026-05-11 | -$219.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $8.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $8.08M derived: sum of 2 quarters · filed 2026-03-09 | -$273.44M derived: sum of 3 quarters · filed 2026-08-05 | -$273.70M 10-K · filed 2026-03-09 |
| 2025-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$281.52M derived: sum of 2 quarters · filed 2026-08-05 | -$281.79M 10-Q · filed 2025-11-06 | -$281.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$281.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$281.79M 10-Q · filed 2026-08-05 | -$281.56M derived: sum of 3 quarters · filed 2026-08-05 | -$281.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$264.00K 10-Q · filed 2026-05-11 | -$33.00K derived: sum of 2 quarters · filed 2026-05-11 | -$200.00K derived: sum of 3 quarters · filed 2026-05-11 | -$188.13M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $64.00K derived: sum of 2 quarters · filed 2026-03-09 | -$187.86M derived: sum of 3 quarters · filed 2026-03-09 | -$186.97M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$167.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$188.09M derived: sum of 2 quarters · filed 2025-11-06 | -$187.21M 10-Q · filed 2025-11-06 | -$186.84M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$187.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$187.04M 10-Q · filed 2025-08-07 | -$186.67M derived: sum of 3 quarters · filed 2025-11-13 | -$175.57M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-03-31 | $887.00K 10-Q · filed 2025-05-12 | $1.25M derived: sum of 2 quarters · filed 2025-11-13 | $12.36M derived: sum of 3 quarters · filed 2025-11-13 | $66.68M derived: sum of 4 quarters · filed 2025-11-13 |
| 2023-12-31 | $366.00K derived: 8-K 12 month − 10-Q 9 month · filed 2025-11-13 | $11.47M derived: sum of 2 quarters · filed 2025-11-13 | $65.80M derived: sum of 3 quarters · filed 2025-11-13 | $69.60M 8-K · filed 2025-11-13 |
| 2023-09-30 | $11.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $65.43M derived: sum of 2 quarters · filed 2024-11-06 | $69.23M 10-Q · filed 2024-11-06 | $75.83M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $54.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $58.13M 10-Q · filed 2024-08-08 | $64.72M derived: sum of 3 quarters · filed 2025-03-17 | $113.59M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $3.80M 10-Q · filed 2024-05-09 | $10.40M derived: sum of 2 quarters · filed 2025-03-17 | $59.26M derived: sum of 3 quarters · filed 2025-03-17 | $59.98M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $6.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $55.46M derived: sum of 2 quarters · filed 2025-03-17 | $56.18M derived: sum of 3 quarters · filed 2025-03-17 | $54.33M 10-K · filed 2025-03-17 |
| 2022-09-30 | $48.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $49.59M derived: sum of 2 quarters · filed 2023-11-06 | $47.73M 10-Q · filed 2023-11-06 | $49.22M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-06-30 | $721.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$1.13M 10-Q · filed 2023-08-02 | $353.00K derived: sum of 3 quarters · filed 2024-03-15 | $1.45M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-03-31 | -$1.85M 10-Q · filed 2023-05-08 | -$368.00K derived: sum of 2 quarters · filed 2024-03-15 | $733.00K derived: sum of 3 quarters · filed 2024-03-15 | $47.59M derived: sum of 4 quarters · filed 2024-03-15 |
| 2021-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $2.59M derived: sum of 2 quarters · filed 2024-03-15 | $49.44M derived: sum of 3 quarters · filed 2024-03-15 | $51.88M 10-K · filed 2024-03-15 |
| 2021-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $47.95M derived: sum of 2 quarters · filed 2022-11-08 | $50.39M 10-Q · filed 2022-11-08 | $55.91M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | $46.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $49.29M 10-Q · filed 2022-08-04 | $54.80M derived: sum of 3 quarters · filed 2023-03-06 | $58.89M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | $2.44M 10-Q · filed 2022-05-05 | $7.95M derived: sum of 2 quarters · filed 2023-03-06 | $12.04M derived: sum of 3 quarters · filed 2023-03-06 | $222.46M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | $5.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $9.60M derived: sum of 2 quarters · filed 2023-03-06 | $220.02M derived: sum of 3 quarters · filed 2023-03-06 | $223.95M 10-K · filed 2023-03-06 |
| 2020-09-30 | $4.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $214.51M derived: sum of 2 quarters · filed 2021-11-08 | $218.43M 10-Q · filed 2021-11-08 | $219.63M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $210.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $214.34M 10-Q · filed 2021-08-05 | $215.54M derived: sum of 3 quarters · filed 2022-02-23 | $219.23M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $3.92M 10-Q · filed 2021-05-06 | $5.12M derived: sum of 2 quarters · filed 2022-02-23 | $8.81M derived: sum of 3 quarters · filed 2022-02-23 | $11.82M derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $4.88M derived: sum of 2 quarters · filed 2022-02-23 | $7.89M derived: sum of 3 quarters · filed 2022-02-23 | $89.37M 10-K · filed 2022-02-23 |
| 2019-09-30 | $3.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $6.69M derived: sum of 2 quarters · filed 2020-11-05 | $88.17M 10-Q · filed 2020-11-05 | $90.76M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $84.49M 10-Q · filed 2020-08-06 | $87.08M derived: sum of 3 quarters · filed 2021-02-25 | $88.14M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $81.48M 10-Q · filed 2020-05-07 | $84.07M derived: sum of 2 quarters · filed 2021-02-25 | $85.13M derived: sum of 3 quarters · filed 2021-02-25 | $185.02M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.65M derived: sum of 2 quarters · filed 2021-02-25 | $103.54M derived: sum of 3 quarters · filed 2021-02-25 | $105.42M 10-K · filed 2021-02-25 |
| 2018-09-30 | $1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $100.95M derived: sum of 2 quarters · filed 2019-11-08 | $102.83M 10-Q · filed 2019-11-08 | $109.72M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $99.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $101.77M 10-Q · filed 2019-08-05 | $108.66M derived: sum of 3 quarters · filed 2020-02-27 | $183.74M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $1.88M 10-Q · filed 2019-05-09 | $8.77M derived: sum of 2 quarters · filed 2020-02-27 | $83.85M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2017-12-31 | $6.89M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $81.97M derived: sum of 2 quarters · filed 2020-02-27 | $206.79M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $75.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $199.90M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $124.81M 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | $226.18M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |